Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab and Capecitabine in Metastatic Colorectal Cancer
NCT00538291Phase 2Terminated
- Sponsor
- City of Hope
- Start
- Aug 2005
- Primary completion
- Feb 2009
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab in colorectal cancer (CRC), sponsored by City of Hope. Primary endpoint: Response Rate up to 1 year. Started Aug 2005; status: terminated.
02
Drugs
cetuximab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT00538291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00538291.